Plain-English translation of NCT06990880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This early-stage trial is testing a new medication called , which is designed to help your immune system fight prostate cancer cells. The study will first find the right dose and then test whether the medication works and is safe in men with advanced prostate cancer that has stopped responding to standard treatments.
Men with advanced, treatment-resistant prostate cancer often run out of effective options. This trial exists to see whether this new immune-based approach can help patients whose cancer has progressed despite previous medications and chemotherapy.
You likely qualify if…
You likely don't qualify if…
The study has two phases: first, researchers will gradually increase doses of the medication in small groups to find the safest dose (Part 1), then expand to more patients at that dose (Part 2). You will receive the medication as an injection or infusion, attend regular clinic visits for blood tests and scans to monitor how you respond, and be asked to follow strict contraception requirements for about 6 months after your treatment ends. The study involves close medical monitoring to check for side effects and measure whether your cancer is responding.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States